From https://projects.propublica.org/docdollars. © Copyright 2013 Pro Publica Inc.
Allergan, headquartered in Irvine, Calif., in September 2010 agreed to pay $600 million to settle criminal and civil claims that it had promoted Botox for unapproved uses.
Allergan began reporting payments made to physicians during the third quarter of 2010. Initially, the company disclosed payments for speaking, consulting and meals, and it reported amounts per doctor in ranges — for example $1-$1,000 or $1,001 to $10,000. It did not break apart spending on each category.
Allergan removed data from its website for the first year of reports and now only has data online for payments made during or after the third quarter of 2011. The payments include the previous categories, plus research payments, educational items, travel and royalties. Allergan still reports payments in ranges and does not break apart spending by category.
Allergan's 2013 U.S. sales: $2.6 billion. Source: IMS Health.
- Botox/Botox Cosmetic/Neuromodulator (wrinkles, migraines, muscle stiffness, muscle spasms, underarm sweating, contraction of eyelid muscles, misalignment of the eyes, glabellar lines, overactive bladder)
- Alphagan P, Alphagan, and Combigan (glaucoma, ocular hypertension)
- Lumigan (glaucoma, ocular hypertension)
- Restasis (dry eye)
- Latisse (insufficient or inadequate eyelashes)
- Juvéderm (severe facial wrinkles and folds)
- Aczone (acne)
2011 July to Dec.
2012 Jan. to Dec.
2013 Jan. to Dec.
Total Payments by State
Because Allergan only discloses ranges for many of its payments, we list only the number of payment records per state.
|District of Columbia||506|